Rabbit Polyclonal Antibody
Catalog No. E27-63R
Catalog No. | Pack Size | Price (USD) | |
---|---|---|---|
E27-63R-100 | 100 ug | $595 | |
E27-63R-BULK | BULK | Contact Us |
Overview:
HER2 gene encodes a cell-surface glycoprotein tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. HER2 is an oncogene and overexpression of unaltered HER2 coding sequences in NIH 3T3 cells results in cellular transformation and tumorigenesis (1). HER2 is amplified in about 30% of primary human breast malignancies and overexpression of HER2 is associated with the most aggressive tumors that show uncontrolled proliferation, resistance to apoptosis and increased motility (2).
References:
1. Hudziak, R M. et al: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A. 1987 Oct; 84(20):7159-63.
2. Badache, A. et al: The ErbB2 Signaling Network as a Target for Breast Cancer Therapy. J Mammary Gland Biol Neoplasia. 2006 Jan; 11(1):13-25.
Specificity:
Recognizes the HER2 protein
Cross Reactivity:
Human, Mouse and Rat
Host / Isotype / Clone#:
Rabbit, IgG
Immunogen:
HER2 antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of human HER2
Purification:
Affinity chromatography
Stability:
Store at 4oC (add 0.1% NaN3) for several months, and at -20oC for longer periods. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Sample Data:
Western blot analysis of HER2 in rat liver tissue lysate with HER2 antibody at (A) 1 and (B) 2 ug/ml.
Sample Data:
Immunohistochemistry of HER2 in human liver tissue with HER2 antibody at 2.5 ug/ml.
Imami Koshi et al., Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways Molecular and Cellular Proteomics September 2012 10.1074/mcp.M112.019919
Y Dunkel et al., Prognostic impact of total and tyrosine phosphorylated GIV/Girdin in breast cancers FASEB Journal November 2016 10.1096/fj.201600500
L. Disis Mary et al., HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers Cancer Immunology, Immunotherapy February 2014 10.1007/s00262-013-1489-4
A Chamas et al., Purification and immunodetection of the complete recombinant HER-2[neu] receptor produced in yeast. Protein Expression and Purification January 2015 10.1016/j.pep.2014.10.004
et al., Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside Biomedicines December 2020
AKT/PKB Pathway, Cancer, Receptor Tyrosine Kinases
STAY CONNECTED
Fax: 1-604-232-4601